A more aggressive regime to stimulate ovarian function is to administer exogenous human gonadotrophin combined with the use of human chorionic gonadotrophin (HCG) to induce ovulation.

This therapy may be used in conjunction with intra-uterine insemination of with IVF treatment. Both forms of treatment will require ultra-sound monitoring in order to assess follicular growth as ovarian hyper stimulation, and thus multiple ovulation, can occur. Treatment protocols for IVF vary from unit to unit but generally a period of down regulation using gonadotrophin releasing hormone (GnRH) agonists are administered to prevent any release of LH from the pituitary. Endogenous FSH production is largely prevented by down regulation, so exogenous FSH is given to stimulate follicular growth and HCG, a protein similar to LH, is given to induce ovulation. Luteal support is essential as GnRH agonist therapy interferes with LH production and the corpus luteum will not function effectively.

Once a diagnosis of Polycystic Ovarian Syndrome has been made and treatment options discussed, the couple may choose not to have any further treatment and either seek advice from health professionals regarding adoption or fostering or remain childless. In Monarch